

Leukocyte Recruitment and Vascular Injury in Diabetic Nephropathy

Elena Galkina and Klaus Ley

Department of Biomedical Engineering and Robert M. Berne Cardiovascular Research Center, University of Virginia, Health Sciences Center, Charlottesville, Virginia

Different types of activated leukocytes play a crucial role in the pathogenesis of most kidney diseases from acute to chronic stages; however, diabetic nephropathy was not considered an inflammatory disease in the past. This view is changing now because there is a growing body of evidence implicating inflammatory cells at every stage of diabetic nephropathy. Renal tissue macrophages, T cells, and neutrophils produce various reactive oxygen species, proinflammatory cytokines, metalloproteinases, and growth factors, which modulate the local response and increase inflammation within the diabetic kidney. Although the precise mechanisms that direct leukocyte homing into renal tissues are not fully identified, it has been reported that intercellular adhesion molecule-1 and the chemokines CCL2 and CX3CL1 probably are involved in leukocyte migration in diabetic nephropathy. This review focuses on the molecular mechanisms of leukocyte recruitment into the diabetic kidney and the involvement of immigrated immune cells in the damage to renal tissues.

J Am Soc Nephrol 17: 368–377, 2006. doi: 10.1681/ASN.2005080859

Diabetic Nephropathy

Diabetic nephropathy (DN) is the leading cause of end-stage renal failure (review in reference [1]). The major features of DN include albuminuria, progressive reduction of GFR, and increased risk for cardiovascular diseases (1–3). DN is associated with the expansion of mesangial cells and development of characteristic features of renal injury, such as thickening of the glomerular basement membrane. In the end, glomerulosclerosis and tubulointerstitial fibrosis are observed in patients with diabetic pathology (4,5). Approximately 30% of patients with type 1 diabetes develop DN (6,7). Barkis *et al.* (8) reported that approximately 25 to 30% of patients with type 2 diabetes will develop overt DN. Recently, several murine models of DN were developed (review in reference [9]). The well-established streptozotocin (STZ)-induced (10–14) and nonobese diabetic (NOD) (15–18) mouse models are most commonly used to study type 1 diabetes. A few models of type 2 diabetes include db/db mice (19,20), ob/ob mice (21), agouti mice on different backgrounds (22,23), and C57BL/6 on high-fat diet (24). Although some features such as the absence of renal failure complicate the interpretations of the studies in murine models, several distinct stages of DN can be detected in murine models (9). Genetically deficient mice that lack different inflammatory molecules are expected to help dissect the molecular mechanisms of initiation and development of DN.

It is well known that hyperglycemia is a major risk factor for DN (25), but hyperglycemia does not account for all changes that are observed in renal tissues (26). It has been suggested that advanced glycation end products (AGE) (27–30), activation of protein kinase C (31), and overexpression of different growth factors (32) are associated with the pathogenesis of DN. Extracellular matrix accumulation is one of the hallmarks in the development of the disease that leads to the formation of glomerular and interstitial lesions (1,26). However, recent studies suggest that inflammatory processes and immune cells might be involved in the development and progression of DN. Infiltrated macrophages are found within renal diabetic tissues, and recent studies demonstrated that macrophage-derived products can induce further inflammation in the diabetic kidney (33–36). Furthermore, activated T lymphocytes have been associated with DN (37,38). One of the most striking features of leukocytes from patients with diabetes is the activated status of blood neutrophils (39,40). There is no doubt that immune cells participate in the vascular injury in the conditions of DN, and their migration into the kidney is a crucial step in the progression of this disease.

Leukocyte Adhesion Cascade

In most organs, leukocyte recruitment is a well-organized cascade-like process that consists of three major steps: (1) Selectin-dependent leukocyte rolling on the endothelial layer, (2) chemokine-dependent integrin activation with subsequent leukocyte adhesion, and (3) diapedesis (41) (Figure 1). The initial capture and rolling is mediated by a family of three type-I cell-surface glycoproteins: L-, P-, and E-selectins (42). L-selectin is expressed on monocytes, granulocytes, and lymphocytes,

Published online ahead of print. Publication date available at www.jasn.org.

Address correspondence to: Dr. Klaus Ley, Robert M. Berne Cardiovascular Research Center, University of Virginia, PO Box 801394, Charlottesville, VA 22908. Phone: 434-243-9966; Fax: 434-924-2828; E-mail: klausley@virginia.edu




Figure 1. Leukocyte adhesion cascade in a glomerular capillary. Monocytes (and other leukocytes; data not shown) are rolling on endothelial cells (blue) *via* E-selectin (blue) and/or P-selectin (green) interacting with P-selectin glycoprotein ligand-1 (PSGL-1) and other ligands. Integrins such as LFA-1 are in the off position (bent conformation). Upon encountering an arrest chemokine (red ellipse on endothelium), signaling through chemokine receptors (red receptor on monocyte) causes conformational activation of LFA-1 and probably other integrins, associated with a more extended conformation (top insert). This enables binding to intercellular adhesion molecule-1 (orange homodimer), upon which integrins cluster by lateral movement in the leukocyte membrane (bottom insert). Stable firm adhesion precedes transmigration (adhesion molecules not shown).

where it plays a crucial role in directing T and B lymphocyte homing into peripheral lymph nodes (43). L-selectin ligands are expressed in high endothelial venules of lymph nodes and collectively are known as peripheral node addressins (44). P-selectin is detected intracellular in α -granules of platelets and in Weibel-Palade bodies of endothelial cells and is released to the plasma membrane upon activation (45). P-selectin binds fucosylated and sialylated O-glycans that are present on a single glycoprotein, P-selectin glycoprotein ligand-1 (PSGL-1). All neutrophils, monocytes, and lymphocytes express PSGL-1, but its functionality as a P-selectin ligand depends on a highly regulated set of glycosylation steps (46). E-selectin expression is not found in most vessels in normal/noninflamed conditions; however, E-selectin expression is rapidly upregulated under inflammatory conditions (47). Recently, PSGL-1 (48) and CD44 (49) were proposed to be ligands for E-selectin, and other ligands may exist. Importantly, the engagement of L-selectin (50), PSGL-1 (51), and E-selectin (52) might lead to leukocyte activation and stabilize arrest under flow. For neutrophils, the successful transition from rolling to adhesion depends on the time the rolling leukocyte interacts with the endothelium (53). Slower rolling velocity provides prolonged time of the leukocyte interaction with endothelial cells that leads to proper activation of leukocytes and successful arrest. Other important factors that will orchestrate the adhesion of rolling leukocytes are arrest chemokines (54).

Arrest chemokines are present on the endothelial surface under physiologic or pathologic conditions, and their interaction with appropriate chemokine receptors on leukocytes will lead to the activation of integrins on rolling cells. From *in vitro* studies, a broad spectrum of chemokines have been suggested to initiate activation of integrins and subsequent leukocyte arrest, but only a few chemokines were identified as arrest chemokines *in vivo*. Secondary lymphoid chemokine (SLC; CCL21) on high endothelial venules induces arrest of naïve and memory T lymphocytes (55). Keratinocyte-derived chemokine (KC; mouse Gro- α , CXCL1), monocyte chemoattractant protein-1 (MCP-1; CCL2), and regulated on activation, normal T cell expressed and secreted (RANTES; CCL5) trigger arrest of rolling monocytes (56–59). There are several reports that demonstrate Gro- α and IL-8 as functional arrest chemokines for neutrophils *in vitro* (60–62), and their receptor CXCR2 is necessary for chemokine-induced neutrophil arrest *in vivo* (63). It also has been recently reported that fractalkine (CX3CL1) induces arrest of CD16⁺ monocytes under flow conditions (64).

When rolling leukocytes receive activation signals through selectin and/or chemokine receptor engagements, integrin activation is initiated (65). Integrins are heterodimeric receptors that consist of α and β subunits that form a ligand-binding head and play a crucial role in leukocyte adhesion (66). *In vitro*, arrest of rolling granulocytes has been shown to be through α_4 integrins (67), $\alpha_L\beta_2$ (LFA-1) (68), and $\alpha_M\beta_2$ -(Mac-1) (69). Two mod-

els of integrin activation have been demonstrated: (1) Conformational changes of integrins that lead to increased receptor affinity and (2) the formation of clusters of heterodimers with increased avidity (70). The best understanding of molecular events comes from analysis of LFA-1/ICAM-1 interactions on lymphocytes. Constantin *et al.* (71) demonstrated that chemokine triggers affinity changes and clustering through distinct signaling pathways. To elucidate the conformational changes during integrin activation, Kim *et al.* applied the method of fluorescence resonance energy transfer (66). In the resting state, α and β subunits of LFA-1 are arranged close to each other; however, upon intracellular activation of integrin adhesiveness (inside-out signaling), this complex undergoes significant spatial separation with opening of the binding site (66). In addition, chemokine-triggered lymphocyte activation induces an extended state that primes LFA-1 for ligand binding and firm adhesion (72,73).

Much has been learned regarding the last step of leukocyte recruitment into inflamed tissues, the process of transmigration (74,75). Several adhesion molecules, such as platelet cells adhesion molecule (76), junctional adhesion molecule-1 (77), and CD99 (78), are involved in the direction of leukocyte transmigration, and β_1 -integrins are involved in leukocyte locomotion in tissues (79).

Immune Cell Recruitment in DN

Little is known about the migration patterns of different types of immune cells into renal tissues in DN. There are two major limitations to studying the impact of immune cells on renal vascular endothelial injury: The limited methods to characterize leukocyte trafficking during inflammation and the limited techniques (80) to estimate the impact of inflammatory mediators that are released by immune cells within the diabetic renal tissues (81). Homing of neutrophils is thought to be a hallmark of acute kidney inflammation, and recruitment of macrophages and T cells indicates chronic inflammatory processes. Although the detailed mechanisms of leukocyte migration to renal tissues are not completely understood, there is evidence that selectins, integrins, and chemokines participate in this recruitment.

Macrophage Recruitment

Macrophages are one of the central mediators of renal vascular inflammation, and their accumulation is a characteristic feature of DN (33–36). Adoptive transfer studies show that macrophages can induce proteinuria and mesangial proliferation in a model of experimental glomerulonephritis (82). Therefore, it is possible that infiltrating macrophages might induce or accelerate the mesangial cell proliferation during the development of DN. Detailed molecular mechanisms that direct macrophage migration are not fully characterized, but chemokines/chemokine receptors as well as integrins are involved in this process. Increased expression of intercellular adhesion molecule (ICAM-1) that serves as a ligand for LFA-1 was detected in models of type 1 (83) and type 2 DN (84,85). ICAM-1 expression can also be induced by factors such as hyperglycemia (31), AGE (86), oxidative stress (87), hyperlipidemia (88),

and hyperinsulinemia (89). The crucial role of ICAM-1 in a model of type 1 diabetes that was induced by a single dose of STZ was shown using ICAM-1-deficient mice (90). Diminished infiltration of macrophages, reduced expression of TGF- β and collagen IV in glomeruli, reduced urinary albumin excretion, glomerular hypertrophy, and mesangial matrix expansion were associated with reduced renal injury in diabetic ICAM-1-deficient mice (90). In a model of type 2 diabetes, Chow *et al.* (91) used ICAM-1-deficient db/db mice and showed significant reduction in albuminuria and a decrease in the number of glomerular and interstitial macrophages that was associated with reduced glomerular hypertrophy, hypercellularity, and tubular damage.

Urinary levels of MCP-1 (CCL2) are significantly increased in patients with DN and are correlated with the number of CD68-positive infiltrating macrophages in the interstitium (92). In addition, both immunohistochemical and *in situ* hybridization analyses revealed MCP-1-positive cells within the tubulointerstitial lesions of human DN (92). MCP-1 is considered to be specifically activated by the transcriptional factor NF- κ B (93), especially in the presence of high glucose (94). Renal expression of MCP-1 is also induced by elevated glucose levels and possibly AGE (95). Inhibition of the renin-angiotensin system improves DN in patients with type 1 and type 2 diabetes through the suppression of renal MCP-1 (96). These results suggest that renal MCP-1 is involved in the direction of macrophage migration into diabetic kidney. Although experiments that evaluate the possible regulation of inflammatory cell influx under conditions of diabetes are not completed yet, there is a promising study indicating that administration of anti-MCP-1 antibodies prevents glomerular sclerosis and interstitial fibrosis (97).

Fractalkine (CX3CL1) is one of the few chemokines that exist in membrane and soluble forms (98), and its expression was detected in human coronary arteries with atherosclerosis and diabetes (99) and in STZ-induced diabetic kidneys along the glomerular capillary lumen and peritubular capillaries (100). Human and murine monocytes express CX3CR1, which is the receptor for fractalkine (101). Increased CX3CR1 mRNA expression was detected in an early stage of diabetic kidney, and some CX3CR1-positive cells seem to be activated macrophages (100). It has been shown that fractalkine induces arrest of CD16⁺ monocytes under flow conditions (64); therefore, it might be possible that within renal tissues, fractalkine functions as an arrest chemokine and serves as one of the factors that induce monocyte adhesion preceding migration into diabetic kidney. The expression of CX3CR1 by T lymphocytes under different inflammatory conditions was reported recently (102,103), and further studies will be necessary to determine the role of this receptor in the T lymphocyte recruitment into the different sites of inflammation. At the present time, it is unclear how macrophage accumulation in interstitium or glomeruli induces major damage in the diabetic kidney. Some studies of other kidney diseases suggest that inflammatory cells accumulating around peritubular capillaries are important sites of cytokine and chemokine production, including IL-1, TNF- α , MCP-1, macrophage-colony stimulating factor, macrophage inflammatory protein-1 β (MIP-1 β ; CCL4), and MIP-2 (CXCL2) in the injured

kidney (104–108). It is interesting that *in vitro* studies have shown that IL-1 β , TNF- α , IFN- γ , and other inflammatory stimuli can induce the production of a broad spectrum of chemokines such as IL-8 (CXCL8), MCP-1, IFN- γ inducible protein (CXCL10), MIP-1 α (CCL3), and RANTES (CCL5) by resident renal cells (109). It is likely that these chemokines might direct the migration of different leukocyte types into renal tissues and induce further inflammation.

T Lymphocyte Recruitment

Although trafficking of naïve, effector, and memory T cells into peripheral lymph nodes, spleen, skin, gut, and liver has been the subject of extensive studies, the mechanisms of T cell homing into the kidney under different pathologic conditions are not fully identified. The fundamental appreciation of the importance of the leukocyte recruitment in the induction of endothelial dysfunction has changed significantly the view of the pathogenesis of DN. Because naïve as well as effector T cells constitutively express LFA-1, and ICAM-1 expression is found on renal endothelial, epithelial, and mesangial cells (83–85), it is likely that this interaction will play a significant role during T cell migration into kidney. Indeed, homing of CD4⁺ T cells into glomeruli of diabetic kidney was decreased in ICAM-1-deficient-db/db mice compared with db/db mice (91). It should be noted that the activation of CD4⁺ and CD8⁺ T cells by AGE can initiate IFN- γ secretion by T cells (110), which will induce further inflammation and oxidative stress within renal tissues.

The role of RANTES in directing of T lymphocyte homing into the diabetic kidney is not clear yet; however, a study of a murine lupus nephritis model identified an important role of RANTES in this disease (111). Moore *et al.* (111) elegantly showed that genetically modified tubular epithelial cells secreting RANTES under the renal capsule increase interstitial nephritis in MRL-*Fas*^{lpr} mice. Moreover, constitutive RANTES expression directs subset-specific homing of CD4⁺ T cells in kidney. T cell accumulation is also found in the juxtaglomerular apparatus of patients with type 1 diabetes (38). The functional role of T cells within this compartment is not clear yet, but this T cell influx is common among young patients with type 1 diabetes, especially those with accelerated duration of diabetes, and correlates with glomerular filtration surface and albumin excretion rate (38).

A T helper-1 (Th1) response precedes and accompanies type 1 diabetes (112); therefore, it is possible that accumulation of Th1 cells will be prevalent in diabetic kidney. Little is known about the homing of Th1 cells during the development and progression of kidney diseases. It has been reported that the homing of effector Th1 cells in glomeruli is P-selectin and ICAM-1 dependent and associated with increased levels of IFN- γ and MIF in crescentic Th1-mediated glomerulonephritis (113). Although the mechanisms of Th1 cell migration in models of DN have not been reported yet, elevated levels of ICAM-1 and P-selectin within the diabetic kidney were found. Further studies will elucidate the possible role of these adhesion molecules in the migration into the diabetic kidney.

Neutrophil Recruitment

Neutrophil influx is associated with the acute response to inflammation or injury. Neutrophils secrete enzymes and products of oxidation that can harm the local microenvironment and induce tissue damage. The role of neutrophils in the development of DN is not well understood; however, there is some evidence that neutrophils might be involved in this pathologic process. Abnormal activation of blood neutrophils has been reported in patients with type 1 and type 2 diabetes (39,40). DN neutrophils failed to remove CD11b (α -subunit of Mac-1) from the cell membrane, and CD11b expression persisted at elevated levels even after a 90-min incubation (39). This elevated expression of CD11b could play a role in the directing of neutrophil migration in the renal inflamed tissues expressing upregulated levels of ICAM-1. In agreement with these data, Tasuji *et al.* (40) showed that spontaneous adhesion of neutrophils from patients with diabetes is increased significantly compared with adhesion of neutrophils from patients with normoalbuminuria as well as healthy control subjects. The precise molecular mechanisms that orchestrate trafficking of neutrophils in diabetic kidney are not yet defined, but studies with other models of kidney pathology suggest that integrins might participate in this process. In an inflammatory model of anti-glomerular basement membrane (GBM) nephritis in rats blocking antibodies for CD18 have revealed an important role of this family of four integrins in the neutrophil homing (114).

A possible role of selectins in the development of DN was suggested by increased expression of selectins in kidneys of patients with diabetes (115). Expressions of E- and P-selectin both were increased in the glomeruli and interstitial capillaries of human diabetic kidneys compared with kidneys of other glomerular diseases (115). E-selectin expression correlated with the influx of CD14⁺ monocytes/macrophages into the interstitium. Several studies have shown elevated selectin expression is associated with high glucose levels (116). AGE likely influence E-selectin expression through AGE receptors expressed by macrophages and endothelial and mesangial cells (117). CD44, a family of type I transmembrane glycoproteins expressed on leukocytes and epithelial and endothelial cells, has been reported to be involved in the neutrophil homing in a model of renal ischemia/reperfusion injury (118). It is interesting that CD44 was proposed recently to be a neutrophil ligand for endothelial E-selectin (49). The impact of this novel mechanism of leukocyte homing in diabetic nephropathy has not been investigated yet.

Role of Immune Cells in Endothelial Dysfunction

Endothelial dysfunction is associated with most forms of cardiovascular diseases, such as coronary artery diseases, chronic renal failure, and diabetes (119,120). There is an increasing body of evidence that immigrated blood leukocytes might significantly alter the phenotype of endothelial cells and increase inflammation of the vascular bed (Table 1).

Macrophages can produce a broad spectrum of potential inducers of renal injury; however, the precise cascade that leads

Table 1. Possible mechanisms of leukocyte recruitment and involvement in the process of diabetic nephropathy^a

Cell Type	Adhesion Molecules, Chemokines	Products	Proposed Role	References
Monocytes, macrophages	ICAM-1, MCP-1	Nitric oxide, reactive oxygen species, IL-1, TNF- α , complement factors, metalloproteinases, PDGF, TGF- β	Endothelial damage, induction of fibroblast and mesangial cell proliferation	(90,91,96,97,128–130, 132–134)
T lymphocytes	LFA-1/ICAM-1, RANTES	IFN- γ , TNF- α	Activation of endothelial cells and macrophages	(91,110)
Neutrophils	Mac-1	Superoxide anion, hydrogen peroxide	Endothelial damage	(40,137)

^aICAM-1, intercellular adhesion molecule-1; MCP, monocyte chemoattractant protein-1; RANTES, regulated on activation, normal T cell exposed and secreted.

to renal injury has yet to be determined. The expression of IL-1, TNF- α , and macrophage MIF is markedly upregulated in the injured kidney (36,109,120–122). Podocytes are considered the major source of IL-1 α and IL-1 β , and at high glucose levels, they may also produce MCP-1 (123,124). These molecules promote inflammation and induce further expression of macrophage colony-stimulating factor and ICAM-1 in renal cells (125–127). Once activated, macrophages release nitric oxide, reactive oxygen species, IL-1, TNF- α , complement factors, and metalloproteinases (128), all of which promote renal injury. Moreover, activated macrophages secrete factors such as PDGF that promote fibroblast proliferation (129). Increased secretion of TGF- β by peripheral blood mononuclear cells was reported in patients with type 1 DN (130). With respect to the interaction between macrophages and mesangial cells, it has been shown that the culture supernatant of macrophages can stimulate mesangial cells to produce fibronectin *in vitro* (131). It should be noted that macrophage-derived factors such as PDGF and IL-1 also can induce mesangial cell proliferation (132,133). Macrophage-derived IL-1 β induces the synthesis of TGF- β that seems to be at least partially responsible for fibrogenic and proliferative effects of IL-1 β on fibroblasts (134). It is interesting that renal fibrosis as measured by TGF- β 1 expression, collagen IV, and interstitial α -smooth muscle actin was dramatically reduced in ICAM-1-deficient mice (91). This is a key event in disease progression, as mice that are deficient in ICAM-1 and, therefore, defective in macrophage homing into renal tissues have shown significant reduction in renal injury (91).

T lymphocytes from patients with diabetes have an activated phenotype (37) and TNF- α -expressing Th1 cells are prevalently detected (112,121). In addition, AGE induce synthesis of IFN- γ that further accelerates the inflammation by the activation of macrophages and vascular cells with the renal tissues.

Usually, neutrophils are the first defense against bacterial infections, because these leukocytes have a broad arsenal of immediate action weapons. However, neutrophils also can induce endothelial dysfunction by production of elevated levels of reactive oxygen species and release of cytotoxic proteinases. NADPH oxidase is a membrane-associated enzyme that generates a family of reactive oxygen species (reviewed in reference

[135]). Upon neutrophil activation, specific granules that contain microbial peptides, proteins, and proteolytic enzymes are released (136). It has been reported that neutrophils from patients with diabetes show increased release of oxygen radicals, such as superoxide anion (40) and hydrogen peroxide (137), that might damage endothelial cells and accelerate the progression of diabetic nephropathy (138,139). There is an increasing body of evidence suggesting that neutrophils from patients with diabetes display an activated phenotype, which is reflected by elevated spontaneous adhesion, TNF- α -stimulated production of superoxide and N-formyl-methionyl-leucyl-phenylalanine-stimulated aggregation in patients with type 2 (140) and type 1 (141) diabetes.

Future Directions

One of the possibilities to reduce diabetic kidney damage may be diminishing T cell and macrophage trafficking. Anti-ICAM-1 antibodies or interventions aimed at reducing levels of oxidative stress, hyperglycemia, and advanced glycation end products may be promising approaches in reducing renal disease in patients with diabetes. Interactions of the chemokine or chemokine receptor levels may provide specific therapies that can curb the development of DN. A better understanding of neutrophil, monocyte, and lymphocyte recruitment in DN is likely to result from mechanistic studies in animal models of DN. Promising mouse models (9) that facilitate this endeavor now are available.

Acknowledgments

We thank Dr. A. Basit for critical reading of the manuscript.

References

- Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: Diagnosis, prevention, and treatment. *Diabetes Care* 28: 164–176, 2005
- Tarnow L, Rossing P, Nielsen FS, Fagerudd JA, Poirier O, Parving HH: Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. *Diabetes Care* 23: 30–33, 2000

3. Young BA, Maynard C, Boyko EJ: Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. *Diabetes Care* 26: 2392–2399, 2003
4. Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM: Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. *N Engl J Med* 320: 966–970, 1989
5. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. *J Clin Invest* 74: 1143–1155, 1984
6. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. *Diabetologia* 25: 496–501, 1983
7. Rossing P, Rossing K, Jacobsen P, Parving HH: Unchanged incidence of diabetic nephropathy in IDDM patients. *Diabetes* 44: 739–743, 1995
8. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. *Am J Kidney Dis* 36: 646–661, 2000
9. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K: Mouse models of diabetic nephropathy. *J Am Soc Nephrol* 16: 27–45, 2005
10. Honjo K, Doi K, Doi C, Mitsuoka T: Histopathology of streptozotocin-induced diabetic DBA/2N and CD-1 mice. *Lab Anim* 20: 298–303, 1986
11. Kimura I, Matsui T, Kimura M: Increase in basal pulse rate and blood pressure by the diabetic state in KK-CAY mice, alloxan-mice and streptozotocin-mice. *Jpn J Pharmacol* 46: 93–96, 1988
12. Leiter EH: Multiple low-dose streptozotocin-induced hyperglycemia and insulinitis in C57BL mice: Influence of inbred background, sex, and thymus. *Proc Natl Acad Sci U S A* 79: 630–634, 1982
13. Wolf J, Lilly F, Shin SI: The influence of genetic background on the susceptibility of inbred mice to streptozotocin-induced diabetes. *Diabetes* 33: 567–571, 1984
14. Zheng F, Striker GE, Esposito C, Lupia E, Striker LJ: Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. *Kidney Int* 54: 1999–2007, 1998
15. Doi T, Hattori M, Agodoa LY, Sato T, Yoshida H, Striker LJ, Striker GE: Glomerular lesions in nonobese diabetic mouse: Before and after the onset of hyperglycemia. *Lab Invest* 63: 204–212, 1990
16. Kolb H: Mouse models of insulin dependent diabetes: Low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. *Diabetes Metab Rev* 3: 751–778, 1987
17. Maeda M, Yabuki A, Suzuki S, Matsumoto M, Taniguchi K, Nishinakagawa H: Renal lesions in spontaneous insulin-dependent diabetes mellitus in the nonobese diabetic mouse: Acute phase of diabetes. *Vet Pathol* 40: 187–195, 2003
18. Watanabe Y, Itoh Y, Yoshida F, Koh N, Tamai H, Fukatsu A, Matsuo S, Hotta N, Sakamoto N: Unique glomerular lesion with spontaneous lipid deposition in glomerular capillary lumina in the NON strain of mice. *Nephron* 58: 210–218, 1991
19. Chua S Jr, Liu SM, Li Q, Yang L, Thassanapaff VT, Fisher P: Differential beta cell responses to hyperglycaemia and insulin resistance in two novel congenic strains of diabetes (FVB- Lep^r (db)) and obese (DBA- Lep^o) mice. *Diabetologia* 45: 976–990, 2002
20. Sharma K, McCue P, Dunn SR: Diabetic kidney disease in the db/db mouse. *Am J Physiol Renal Physiol* 284: F1138–F1144, 2003
21. Velasquez MT, Kimmel PL, Michaelis OE: Animal models of spontaneous diabetic kidney disease. *FASEB J* 4: 2850–2859, 1990
22. Hustad CM, Perry WL, Siracusa LD, Raspberry C, Cobb L, Cattanch BM, Kovatch R, Copeland NG, Jenkins NA: Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus. *Genetics* 140: 255–265, 1995
23. Suto J, Matsuura S, Imamura K, Yamanaka H, Sekikawa K: Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-Ay mice. *Eur J Endocrinol* 139: 654–661, 1998
24. Noonan WT, Banks RO: Renal function and glucose transport in male and female mice with diet-induced type II diabetes mellitus. *Proc Soc Exp Biol Med* 225: 221–230, 2000
25. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. *N Engl J Med* 332: 1251–1255, 1995
26. Deckert T, Poulsen JE: Diabetic nephropathy: Fault or destiny? *Diabetologia* 21: 178–183, 1981
27. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. *J Clin Invest* 87: 432–438, 1991
28. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA: Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: Role of advanced glycation end products. *J Am Soc Nephrol* 15: 2125–2138, 2004
29. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. *N Engl J Med* 325: 836–842, 1991
30. Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin JL, Hofmann SM, Vlassara H, Shi Y: Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. *Circulation* 108: 472–478, 2003
31. Park CW, Kim JH, Lee JH, Kim YS, Ahn HJ, Shin YS, Kim SY, Choi EJ, Chang YS, Bang BK: High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. *Diabetologia* 43: 1544–1553, 2000
32. Wolf G: New insights into the pathophysiology of diabetic nephropathy: From haemodynamics to molecular pathology. *Eur J Clin Invest* 34: 785–796, 2004
33. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA: The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. *Pathol Res Pract* 187: 251–259, 1991
34. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K: The role of macrophages in diabetic glomerulosclerosis. *Am J Kidney Dis* 21: 480–485, 1993
35. Sassy-Prigent C, Heudes D, Mandet C, Belair MF, Michel

- O, Perdereau B, Bariety J, Bruneval P: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. *Diabetes* 49: 466–475, 2000
36. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury. *Kidney Int* 65: 116–128, 2004
37. Bending JJ, Lobo-Yeo A, Vergani D, Viberti GC: Proteinuria and activated T-lymphocytes in diabetic nephropathy. *Diabetes* 37: 507–511, 1988
38. Moriya R, Manivel JC, Mauer M: Juxtaglomerular apparatus T-cell infiltration affects glomerular structure in type 1 diabetic patients. *Diabetologia* 47: 82–88, 2004
39. Fardon NJ, Wilkinson R, Thomas TH: Abnormalities in primary granule exocytosis in neutrophils from type I diabetic patients with nephropathy. *Clin Sci (Lond)* 102: 69–75, 2002
40. Takahashi T, Hato F, Yamane T, Inaba M, Okuno Y, Nishizawa Y, Kitagawa S: Increased spontaneous adherence of neutrophils from type 2 diabetic patients with overt proteinuria: Possible role of the progression of diabetic nephropathy. *Diabetes Care* 23: 417–418, 2000
41. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. *Cell* 76: 301–314, 1994
42. Kansas GS: Selectins and their ligands: Current concepts and controversies. *Blood* 88: 3259–3287, 1996
43. Arbones ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, Otten G, Capon DJ, Tedder TF: Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. *Immunity* 1: 247–260, 1994
44. Rosen SD: Ligands for L-selectin: Where and how many? *Res Immunol* 144: 699–703, 1993
45. McEver RP: Regulation of function and expression of P-selectin. *Agents Actions Suppl* 47: 117–119, 1995
46. Ley K, Kansas GS: Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. *Nat Rev Immunol* 4: 325–335, 2004
47. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr: Identification of an inducible endothelial-leukocyte adhesion molecule. *Proc Natl Acad Sci U S A* 84: 9238–9242, 1987
48. Katayama Y, Hidalgo A, Furie BC, Vestweber D, Furie B, Frenette PS: PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: Evidence for cooperation between E-selectin ligands and alpha4 integrin. *Blood* 102: 2060–2067, 2003
49. Katayama Y, Hidalgo A, Chang J, Peired A, Frenette PS: CD44 is a physiological E-selectin ligand on neutrophils. *J Exp Med* 201: 1183–1189, 2005
50. Hafezi-Moghadam A, Thomas KL, Prorock AJ, Huo Y, Ley K: L-selectin shedding regulates leukocyte recruitment. *J Exp Med* 193: 863–872, 2001
51. Moore KL: Structure and function of P-selectin glycoprotein ligand-1. *Leuk Lymphoma* 29: 1–15, 1998
52. Yoshida M, Sente BE, Kiely JM, Rosenzweig A, Gimbrone MA Jr: Phosphorylation of the cytoplasmic domain of E-selectin is regulated during leukocyte-endothelial adhesion. *J Immunol* 161: 933–941, 1998
53. Jung U, Norman KE, Scharffetter-Kochanek K, Beaudet AL, Ley K: Transit time of leukocytes rolling through venules controls cytokine-induced inflammatory cell recruitment in vivo. *J Clin Invest* 102: 1526–1533, 1998
54. Ley K: Arrest chemokines. *Microcirculation* 10: 289–295, 2003
55. Stein JV, Rot A, Luo Y, Narasimhaswamy M, Nakano H, Gunn MD, Matsuzawa A, Quackenbush EJ, Dorf ME, von Andrian UH: The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. *J Exp Med* 191: 61–76, 2000
56. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinskas FW, Rosenzweig A: MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. *Nature* 398: 718–723, 1999
57. Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K: The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. *J Clin Invest* 108: 1307–1314, 2001
58. Palframan RT, Jung S, Cheng G, Weninger W, Luo Y, Dorf M, Littman DR, Rollins BJ, Zweerink H, Rot A, von Andrian UH: Inflammatory chemokine transport and presentation in HEV: A remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. *J Exp Med* 194: 1361–1373, 2001
59. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C: RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. *Circulation* 103: 1772–1777, 2001
60. Campbell JJ, Qin S, Bacon KB, Mackay CR, Butcher EC: Biology of chemokine and classical chemoattractant receptors: Differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. *J Cell Biol* 134: 255–266, 1996
61. Rainger GE, Fisher AC, Nash GB: Endothelial-borne platelet-activating factor and interleukin-8 rapidly immobilize rolling neutrophils. *Am J Physiol* 272: H114–H122, 1997
62. Rot A: Endothelial cell binding of NAP-1/IL-8: Role in neutrophil emigration. *Immunol Today* 13: 291–294, 1992
63. Smith ML, Olson TS, Ley K: C. CXCR2- and E-selectin-induced neutrophil arrest during inflammation in vivo. *J Exp Med* 200: 935–939, 2004
64. Ancuta P, Rao R, Moses A, Mehle A, Shaw SK, Luscinskas FW, Gabuzda D: Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. *J Exp Med* 197: 1701–1707, 2003
65. Hogg N, Henderson R, Leitinger B, McDowall A, Porter J, Stanley P: Mechanisms contributing to the activity of integrins on leukocytes. *Immunol Rev* 186: 164–171, 2002
66. Kim M, Carman CV, Springer TA: Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. *Science* 301: 1720–1725, 2003
67. Kitayama J, Fuhlbrigge RC, Puri KD, Springer TA: P-selectin, L-selectin, and alpha 4 integrin have distinct roles in eosinophil tethering and arrest on vascular endothelial cells under physiological flow conditions. *J Immunol* 159: 3929–3939, 1997
68. Lawrence MB, Springer TA: Leukocytes roll on a selectin at

- physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. *Cell* 65: 859–873, 1991
69. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA: Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. *Blood* 88: 146–157, 1996
70. Bazzoni G, Hemler ME: Are changes in integrin affinity and conformation overemphasized? *Trends Biochem Sci* 23: 30–34, 1998
71. Constantin G, Majeed M, Giagulli C, Piccio L, Kim JY, Butcher EC, Laudanna C: Chemokines trigger immediate beta2 integrin affinity and mobility changes: Differential regulation and roles in lymphocyte arrest under flow. *Immunity* 13: 759–769, 2000
72. Salas A, Shimaoka M, Kogan AN, Harwood C, von Andrian UH, Springer TA: Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta1-like domain interaction. *Immunity* 20: 393–406, 2004
73. Shamri R, Grabovsky V, Gauguet JM, Feigelson S, Manevich E, Kolanus W, Robinson MK, Staunton DE, von Andrian UH, Alon R: Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. *Nat Immunol* 6: 497–506, 2005
74. Muller WA: Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. *Trends Immunol* 24: 327–334, 2003
75. Vestweber D: Regulation of endothelial cell contacts during leukocyte extravasation. *Curr Opin Cell Biol* 14: 587–593, 2002
76. Muller WA, Weigl SA, Deng X, Phillips DM: PECAM-1 is required for transendothelial migration of leukocytes. *J Exp Med* 178: 449–460, 1993
77. Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, Dejana E: Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. *J Cell Biol* 142: 117–127, 1998
78. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA: CD99 plays a major role in the migration of monocytes through endothelial junctions. *Nat Immunol* 3: 143–150, 2002
79. Werr J, Xie X, Hedqvist P, Ruoslahti E, Lindbom L: Beta1 integrins are critically involved in neutrophil locomotion in extravascular tissue in vivo. *J Exp Med* 187: 2091–2096, 1998
80. De Vriese AS, Endlich K, Elger M, Lameire NH, Atkins RC, Lan HY, Rupin A, Kriz W, Steinhausen MW: The role of selectins in glomerular leukocyte recruitment in rat anti-glomerular basement membrane glomerulonephritis. *J Am Soc Nephrol* 10: 2510–2517, 1999
81. Siragy HM, Carey RM: The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3',5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. *J Clin Invest* 97: 1978–1982, 1996
82. Ikezumi Y, Hurst LA, Masaki T, Atkins RC, Nikolic-Paterson DJ: Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. *Kidney Int* 63: 83–95, 2003
83. Sugimoto H, Shikata K, Hirata K, Akiyama K, Matsuda M, Kushiro M, Shikata Y, Miyatake N, Miyasaka M, Makino H: Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: Glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. *Diabetes* 46: 2075–2081, 1997
84. Matsui H, Suzuki M, Tsukuda R, Iida K, Miyasaka M, Ikeda H: Expression of ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically obese diabetic rat, Wistar fatty. *Diabetes Res Clin Pract* 32: 1–9, 1996
85. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J: Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. *Kidney Int* 57: 167–182, 2000
86. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R: Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses. *Circulation* 105: 816–822, 2002
87. Onozato ML, Tojo A, Goto A, Fujita T: Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. *Kidney Int* 65: 951–960, 2004
88. Hattori M, Nikolic-Paterson DJ, Miyazaki K, Isbel NM, Lan HY, Atkins RC, Kawaguchi H, Ito K: Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. *Kidney Int Suppl* 71: S47–S50, 1999
89. Okouchi M, Okayama N, Shimizu M, Omi H, Fukutomi T, Itoh M: High insulin exacerbates neutrophil-endothelial cell adhesion through endothelial surface expression of intercellular adhesion molecule-1 via activation of protein kinase C and mitogen-activated protein kinase. *Diabetologia* 45: 556–559, 2002
90. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H: Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. *Diabetes* 52: 2586–2593, 2003
91. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH: Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. *J Am Soc Nephrol* 16: 1711–1722, 2005
92. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H: Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. *Kidney Int* 58: 1492–1499, 2000
93. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T: Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. *J Biol Chem* 272: 31092–31099, 1997
94. Bierhaus A, Schiekofler S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. *Diabetes* 50: 2792–2808, 2001
95. Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ, Cha

- DR, Ha H: A high glucose concentration stimulates the expression of monocyte chemoattractant peptide 1 in human mesangial cells. *Nephron* 79: 33–37, 1998
96. Amann B, Tinzmann R, Angelkort B: ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. *Diabetes Care* 26: 2421–2425, 2003
97. Wada T, Yokoyama H, Furuichi K, Kobayashi KI, Harada K, Naruto M, Su SB, Akiyama M, Mukaida N, Matsushima K: Intervention of crescentic glomerulonephritis by antibodies to monocyte chemoattractant and activating factor (MCAF/MCP-1). *FASEB J* 10: 1418–1425, 1996
98. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. *Nature* 385: 640–644, 1997
99. Wong BW, Wong D, McManus BM: Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. *Cardiovasc Pathol* 11: 332–338, 2002
100. Kikuchi Y, Ikee R, Hemmi N, Hyodo N, Saigusa T, Namikoshi T, Yamada M, Suzuki S, Miura S: Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. *Nephron Exp Nephrol* 97: e17–e25, 2004
101. Geissmann F, Jung S, Littman DR: Blood monocytes consist of two principal subsets with distinct migratory properties. *Immunity* 19: 71–82, 2003
102. Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K, Hayashida K, Hasegawa J, Yoshie O, Miyasaka N: Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. *Arthritis Rheum* 46: 2878–2883, 2002
103. Isse K, Harada K, Zen Y, Kamihira T, Shimoda S, Harada M, Nakanuma Y: Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. *Hepatology* 41: 506–516, 2005
104. Chakravorty SJ, Cockwell P, Girdlestone J, Brooks CJ, Savage CO: Fractalkine expression on human renal tubular epithelial cells: Potential role in mononuclear cell adhesion. *Clin Exp Immunol* 129: 150–159, 2002
105. Cockwell P, Calderwood JW, Brooks CJ, Chakravorty SJ, Savage CO: Chemoattraction of T cells expressing CCR5, CXCR3 and CX3CR1 by proximal tubular epithelial cell chemokines. *Nephrol Dial Transplant* 17: 734–744, 2002
106. Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Takei M, Ito S: Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. *J Diabetes Complications* 17: 11–15, 2003
107. Tesch GH, Schwarting A, Kinoshita K, Lan HY, Rollins BJ, Kelley VR: Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. *J Clin Invest* 103: 73–80, 1999
108. Yu XQ, Nikolic-Paterson DJ, Mu W, Giachelli CM, Atkins RC, Johnson RJ, Lan HY: A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. *Proc Assoc Am Physicians* 110: 50–64, 1998
109. Segerer S, Nelson PJ, Schlondorff D: Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. *J Am Soc Nephrol* 11: 152–176, 2000
110. Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V, Sehajpal P, Vlassara H: Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: Role in tissue remodeling. *J Exp Med* 178: 2165–2172, 1993
111. Moore KJ, Wada T, Barbee SD, Kelley VR: Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas(1pr) mice. *Kidney Int* 53: 1631–1641, 1998
112. Castano L, Eisenbarth GS: Type-I diabetes: A chronic autoimmune disease of human, mouse, and rat. *Annu Rev Immunol* 8: 647–679, 1990
113. Odobasic D, Kitching AR, Tipping PG, Holdsworth SR: CD80 and CD86 costimulatory molecules regulate crescentic glomerulonephritis by different mechanisms. *Kidney Int* 68: 584–594, 2005
114. Wu X, Tiwari AK, Issekutz TB, Lefkowitz JB: Differing roles of CD18 and VLA-4 in leukocyte migration/activation during anti-GBM nephritis. *Kidney Int* 50: 462–472, 1996
115. Hirata K, Shikata K, Matsuda M, Akiyama K, Sugimoto H, Kushiro M, Makino H: Increased expression of selectins in kidneys of patients with diabetic nephropathy. *Diabetologia* 41: 185–192, 1998
116. Kim JA, Berliner JA, Natarajan RD, Nadler JL: Evidence that glucose increases monocyte binding to human aortic endothelial cells. *Diabetes* 43: 1103–1107, 1994
117. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H: Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodeling and diabetic nephropathy. *J Exp Med* 174: 931–939, 1991
118. Rouschop KM, Roelofs JJ, Claessen N, Martins PC, Zwaginga JJ, Pals ST, Weening JJ, Florquin S: Protection against renal ischemia reperfusion injury by CD44 disruption. *J Am Soc Nephrol* 16: 2034–2043, 2005
119. Endemann DH, Schiffrin EL: Endothelial dysfunction. *J Am Soc Nephrol* 15: 1983–1992, 2004
120. Stehouwer CD: Endothelial dysfunction in diabetic nephropathy: State of the art and potential significance for non-diabetic renal disease. *Nephrol Dial Transplant* 19: 778–781, 2004
121. Mensah-Brown EP, Obineche EN, Galadari S, Chandranath E, Shahin A, Ahmed I, Patel SM, Adem A: Streptozotocin-induced diabetic nephropathy in rats: The role of inflammatory cytokines. *Cytokine* 31: 180–190, 2005
122. Sterzel RB, Schulze-Lohoff E, Marx M: Cytokines and mesangial cells. *Kidney Int Suppl* 39: S26–S31, 1993
123. Han SY, So GA, Jee YH, Han KH, Kang YS, Kim HK, Kang SW, Han DS, Han JY, Cha DR: Effect of retinoic acid in experimental diabetic nephropathy. *Immunol Cell Biol* 82: 568–576, 2004
124. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H: Expression of functional CCR and CXCR chemokine receptors in podocytes. *J Immunol* 168: 6244–6252, 2002
125. Frank J, Engler-Blum G, Rodemann HP, Muller GA: Human renal tubular cells as a cytokine source: PDGF-B, GM-CSF and IL-6 mRNA expression in vitro. *Exp Nephrol* 1: 26–35, 1993
126. Nikolic-Paterson DJ, Lan HY, Hill PA, Vannice JL, Atkins

- RC: Suppression of experimental glomerulonephritis by the interleukin-1 receptor antagonist: Inhibition of intercellular adhesion molecule-1 expression. *J Am Soc Nephrol* 4: 1695–1700, 1994
127. Rovin BH, Yoshiumura T, Tan L: Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. *J Immunol* 148: 2148–2153, 1992
128. Nikolic-Paterson DJ, Atkins RC: The role of macrophages in glomerulonephritis. *Nephrol Dial Transplant* 16[Suppl 5]: 3–7, 2001
129. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in streptozotocin-induced diabetic nephropathy: Potential role in renal fibrosis. *Nephrol Dial Transplant* 19: 2987–2996, 2004
130. Korpinen E, Groop PH, Fagerudd JA, Teppo AM, Akerman HK, Vaarala O: Increased secretion of TGF-beta1 by peripheral blood mononuclear cells from patients with type 1 diabetes mellitus with diabetic nephropathy. *Diabet Med* 18: 121–125, 2001
131. Pawluczyk IZ, Harris KP: Macrophages promote prosclerotic responses in cultured rat mesangial cells: A mechanism for the initiation of glomerulosclerosis. *J Am Soc Nephrol* 8: 1525–1536, 1997
132. Stahl RA, Thaiss F, Haberstroh U, Kahf S, Shaw A, Schoppa W: Cyclooxygenase inhibition enhances rat interleukin 1 beta-induced growth of rat mesangial cells in culture. *Am J Physiol* 259: F419–F424, 1990
133. Floege J, Topley N, Hoppe J, Barrett TB, Resch K: Mitogenic effect of platelet-derived growth factor in human glomerular mesangial cells: Modulation and/or suppression by inflammatory cytokines. *Clin Exp Immunol* 86: 334–341, 1991
134. Vesey DA, Cheung C, Cuttle L, Endre Z, Gobe G, Johnson DW: Interleukin-1beta stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-beta-dependent mechanism. *J Lab Clin Med* 140: 342–350, 2002
135. Lambeth JD: NOX enzymes and the biology of reactive oxygen. *Nat Rev Immunol* 4: 181–189, 2004
136. Burg ND, Pillinger MH: The neutrophil: Function and regulation in innate and humoral immunity. *Clin Immunol* 99: 7–17, 2001
137. Watanabe A, Tomino Y, Yokoyama K, Koide H: Production of hydrogen peroxide by neutrophilic polymorphonuclear leukocytes in patients with diabetic nephropathy. *J Clin Lab Anal* 7: 209–213, 1993
138. Baynes JW: Role of oxidative stress in development of complications in diabetes. *Diabetes* 40: 405–412, 1991
139. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T: Oxidative damage to DNA in diabetes mellitus. *Lancet* 347: 444–445, 1996
140. Ohmori M, Harada K, Kitoh Y, Nagasaka S, Saito T, Fujimura A: The functions of circulatory polymorphonuclear leukocytes in diabetic patients with and without diabetic triopathy. *Life Sci* 66: 1861–1870, 2000
141. Abu el-Asrar AM, Soliman RT, al Amro SA, al Shammery FJ: Production of superoxide anion by polymorphonuclear leukocytes from diabetic patients with or without diabetic retinopathy. *Doc Ophthalmol* 91: 243–254, 1995